Effectiveness of interventions to improve medication adherence in adults with depressive disorders: a meta-analysis.

Tytuł:: Effectiveness of interventions to improve medication adherence in adults with depressive disorders: a meta-analysis.
Autorzy:: González de León B; Unidad Docente Multiprofesional de Atención Familiar y Comunitaria 'La Laguna ‑ Tenerife Norte', Gerencia de Atención Primaria del Área de Salud de Tenerife, Santa Cruz de Tenerife, Spain.
Del Pino-Sedeño T; Fundación Canaria Instituto de Investigación Sanitaria de Canarias (FIISC), Santa Cruz de Tenerife, Spain. .; Servicio de Evaluación y Planificación del Servicio Canario de La Salud, Santa Cruz de Tenerife, Spain. .
Serrano-Pérez P; Servicio de Psiquiatría, Hospital Universitario Vall d'Hebron, Barcelona, Spain.; Departamento de Psiquiatría Y Medicina Legal, Universidad Autónoma de Barcelona, Barcelona, Spain.; Grupo de Investigación en Psiquiatría, Salud Mental Y Adicciones, Vall d'Hebron Instituto de Investigación (VHIR), Barcelona, Spain.
Rodríguez Álvarez C; Campus Ciencias de La Salud. Área de Medicina Preventiva y Salud Pública. Universidad de La Laguna, Santa Cruz de Tenerife, Spain.
Bejarano-Quisoboni D; Centro Superior de Investigación en Salud Pública (CSISP-FISABIO), Valencia, Spain.; Red de Investigación en Servicios de Salud en Enfermedades Crónicas (REDISSEC), Madrid, Spain.
Trujillo-Martín MM; Fundación Canaria Instituto de Investigación Sanitaria de Canarias (FIISC), Santa Cruz de Tenerife, Spain.; Red de Investigación en Servicios de Salud en Enfermedades Crónicas (REDISSEC), Madrid, Spain.
Źródło:: BMC psychiatry [BMC Psychiatry] 2022 Jul 20; Vol. 22 (1), pp. 487. Date of Electronic Publication: 2022 Jul 20.
Typ publikacji:: Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't
Język:: English
Imprint Name(s):: Original Publication: London : BioMed Central, [2001-
MeSH Terms:: Depressive Disorder*/drug therapy
Medication Adherence*
Adult ; Antidepressive Agents/therapeutic use ; Anxiety ; Humans ; Systematic Reviews as Topic
References:: Health Technol Assess. 2016 Feb;20(14):1-192. (PMID: 26910256)
BMJ. 2021 Mar 29;372:n71. (PMID: 33782057)
Int Clin Psychopharmacol. 2015 Nov;30(6):316-9. (PMID: 26163876)
J Behav Health Serv Res. 2014 Oct;41(4):529-38. (PMID: 23702612)
Arch Gen Psychiatry. 1996 Oct;53(10):924-32. (PMID: 8857869)
J Affect Disord. 2013 Jul;149(1-3):14-22. (PMID: 23545062)
J Clin Psychiatry. 2018 May/Jun;79(3):. (PMID: 29068611)
J Affect Disord. 2010 Jun;123(1-3):216-21. (PMID: 19914719)
J Clin Psychiatry. 2003 Dec;64(12):1415-20. (PMID: 14728101)
Syst Rev. 2018 Jan 22;7(1):10. (PMID: 29357926)
Control Clin Trials. 1986 Sep;7(3):177-88. (PMID: 3802833)
Health Technol Assess. 2014 May;18(31):1-167, vii-viii. (PMID: 24824481)
Lancet. 2013 Feb 2;381(9864):375-84. (PMID: 23219570)
Hosp Pharm. 2022 Feb;57(1):26-31. (PMID: 35521002)
J Clin Psychopharmacol. 2002 Oct;22(5):474-80. (PMID: 12352270)
Nord J Psychiatry. 2010 Aug;64(4):265-7. (PMID: 20166864)
Psychiatr Serv. 2014 Aug 1;65(8):1058-61. (PMID: 25082605)
Prog Neuropsychopharmacol Biol Psychiatry. 2002 Apr;26(3):591-6. (PMID: 11999913)
J Affect Disord. 2016 Aug;200:189-203. (PMID: 27136418)
Br J Clin Pharmacol. 2012 May;73(5):691-705. (PMID: 22486599)
J Am Pharm Assoc (2003). 2006 Jan-Feb;46(1):25-32. (PMID: 16529338)
Psychol Med. 2005 Jan;35(1):25-33. (PMID: 15842026)
J Gen Intern Med. 2010 Apr;25(4):284-90. (PMID: 20131023)
J Gen Intern Med. 2011 Jul;26(7):698-704. (PMID: 21384219)
J Affect Disord. 2018 Feb;227:613-617. (PMID: 29172054)
Patient Educ Couns. 2008 Jul;72(1):94-101. (PMID: 18337052)
Am J Psychiatry. 1999 Apr;156(4):643-5. (PMID: 10200750)
JAMA. 1995 Apr 5;273(13):1026-31. (PMID: 7897786)
Gen Hosp Psychiatry. 2003 Sep-Oct;25(5):303-10. (PMID: 12972220)
J Affect Disord. 2001 May;64(2-3):217-29. (PMID: 11313088)
Int J Environ Res Public Health. 2021 Sep 28;18(19):. (PMID: 34639510)
Curr Opin Psychiatry. 2014 Sep;27(5):344-9. (PMID: 25033275)
J Am Coll Health. 2015;63(3):204-8. (PMID: 25338175)
Psychol Med. 2006 Mar;36(3):325-33. (PMID: 16332282)
J Am Board Fam Med. 2014 Sep-Oct;27(5):621-36. (PMID: 25201932)
Int Clin Psychopharmacol. 2003 Nov;18(6):347-54. (PMID: 14571155)
J Affect Disord. 2016 Mar 15;193:1-10. (PMID: 26748881)
Lancet. 2018 Nov 10;392(10159):1789-1858. (PMID: 30496104)
J Gen Intern Med. 2002 Oct;17(10):741-8. (PMID: 12390549)
Br J Clin Pharmacol. 1984 Jan;17(1):21-5. (PMID: 6691885)
Behav Cogn Psychother. 2014 Jul;42(4):497-501. (PMID: 23829940)
Depress Anxiety. 2013 Jul;30(7):688-96. (PMID: 23300127)
BMC Psychiatry. 2015 Sep 16;15:219. (PMID: 26376830)
J Med Internet Res. 2017 Nov 03;19(11):e373. (PMID: 29101095)
Adm Policy Ment Health. 2012 Sep;39(5):374-82. (PMID: 21553144)
Indian J Psychiatry. 2016 Oct-Dec;58(4):425-431. (PMID: 28197000)
BMJ. 2016 Oct 12;355:i4919. (PMID: 27733354)
Prim Care Companion J Clin Psychiatry. 2009;11(2):48-52. (PMID: 19617933)
Br J Psychiatry. 2002 Feb;180:104-9. (PMID: 11823317)
Depress Anxiety. 2001;13(1):1-10. (PMID: 11233454)
Arch Psychiatr Nurs. 2016 Jun;30(3):322-8. (PMID: 27256936)
Front Pharmacol. 2013 Jul 25;4:91. (PMID: 23898295)
J Int Med Res. 1976;4(4):237-40. (PMID: 1026548)
Arch Gen Psychiatry. 2001 Mar;58(3):241-7. (PMID: 11231831)
J Am Pharm Assoc (2003). 2005 May-Jun;45(3):344-53. (PMID: 15991756)
Am J Health Syst Pharm. 2004 Feb 15;61(4):364-72. (PMID: 15011764)
J Med Internet Res. 2010 Dec 19;12(5):e63. (PMID: 21172765)
J Am Pharm Assoc (2003). 2013 Mar-Apr;53(2):172-81. (PMID: 23571625)
J Affect Disord. 2002 Apr;68(2-3):317-30. (PMID: 12063159)
J Affect Disord. 2016 Apr;194:202-21. (PMID: 26851552)
Int J Clin Pract. 2015 Aug;69(8):889-99. (PMID: 25728214)
J Affect Disord. 2022 Aug 15;311:582-587. (PMID: 35598746)
J Affect Disord. 2008 May;108(1-2):33-41. (PMID: 17905442)
Diabet Med. 2016 May;33(5):565-79. (PMID: 26470750)
JAMA Intern Med. 2015 Nov;175(11):1761-70. (PMID: 26414670)
Int J Clin Health Psychol. 2018 May-Aug;18(2):133-142. (PMID: 30487918)
Psychiatr Serv. 2006 Oct;57(10):1441-5. (PMID: 17035563)
Am J Psychiatry. 2015 Oct;172(10):1004-13. (PMID: 26315978)
Indian J Med Res. 2014 Feb;139(2):236-45. (PMID: 24718398)
Int J Clin Pract. 2011 Sep;65(9):954-75. (PMID: 21849010)
Front Pharmacol. 2016 Nov 14;7:429. (PMID: 27895583)
Int J Pharm Pract. 2013 Aug;21(4):252-62. (PMID: 23418704)
Gen Hosp Psychiatry. 2004 May-Jun;26(3):199-209. (PMID: 15121348)
CNS Drugs. 2017 May;31(5):421-432. (PMID: 28378157)
Aust J Rural Health. 2006 Dec;14(6):263-9. (PMID: 17121506)
Arch Gen Psychiatry. 1999 Dec;56(12):1109-15. (PMID: 10591288)
Contributed Indexing:: Keywords: Major Depressive Disorder; Meta-analysis; Systematic review; Treatment Adherence
Substance Nomenclature:: 0 (Antidepressive Agents)
Entry Date(s):: Date Created: 20220720 Date Completed: 20220722 Latest Revision: 20220726
Update Code:: 20240105
PubMed Central ID:: PMC9301839
DOI:: 10.1186/s12888-022-04120-w
PMID:: 35858887
: Czasopismo naukowe

Pełny tekst

Background: Non-adherence to medication is a major obstacle in the treatment of depressive disorders. We systematically reviewed the literature to evaluate the effectiveness of interventions aimed at improving adherence to medication among adults with depressive disorders with emphasis on initiation and implementation phase.
Methods: We searched Medline, EMBASE, The Cochrane Central Register of Controlled Trials (CENTRAL), PsycINFO, Social Science Citation Index and Science Citation Index for randomized or non-randomized controlled trials up to January 2022. Risk of bias was assessed using the criteria of the Cochrane Collaboration. Meta-analyses, cumulative and meta-regression analyses for adherence were conducted.
Results: Forty-six trials (n = 24,324) were included. Pooled estimate indicates an increase in the probability of adherence to antidepressants at 6 months with the different types of interventions (OR 1.33; 95% CI: 1.09 to 1.62). The improvement in adherence is obtained from 3 months (OR 1.62, 95% CI: 1.25 to 2.10) but it is attenuated at 12 months (OR 1.25, 95% CI: 1.02 to 1.53). Selected articles show methodological differences, mainly the diversity of both the severity of the depressive disorder and intervention procedures. In the samples of these studies, patients with depression and anxiety seem to benefit most from intervention (OR 2.77, 95% CI: 1.74 to 4.42) and collaborative care is the most effective intervention to improve adherence (OR 1.88, 95% CI: 1.40 to 2.54).
Conclusions: Our findings indicate that interventions aimed at improving adherence to medication among adults with depressive disorders are effective up to six months. However, the evidence on the effectiveness of long-term adherence is insufficient and supports the need for further research efforts.
Trial Registration: International Prospective Register for Systematic Reviews (PROSPERO) number: CRD42017065723 .
(© 2022. The Author(s).)

Zaloguj się, aby uzyskać dostęp do pełnego tekstu.

Informacja